Brown for BI: An Evidence-Based Review of Prostate Cancer Screening, Diagnosis, and Treatment Pathways

Prostate cancer is a malignant neoplasm arising from glandular epithelial cells of the prostate. It is among the most common cancers in men and displays a wide spectrum of clinical behavior, ranging from indolent disease that may never cause harm to aggressive tumors that metastasize. Clinicians approach prostate cancer through risk stratification, screening (where appropriate), confirmatory diagnostics, staging, and selection of therapy based on grade, extent, and patient preferences.

Risk factors include increasing age, family history (particularly first-degree relatives with early-onset disease), inherited genetic variants (e.g., BRCA2 and other DNA repair genes), and ancestry-associated risk differences. Although dietary and hormonal influences have been studied, the strongest actionable factors remain age and genetic/familial predisposition. Clinically, prostate cancer may be asymptomatic, which is why biomarkers and imaging are central to early detection. When symptomatic, findings can involve lower urinary tract symptoms (hesitancy, weak stream, nocturia) and, in advanced disease, bone pain from metastases.

Screening debates center on balancing early detection benefits against harms such as false positives, overdiagnosis, overtreatment, and procedure-related morbidity. Common screening tools include prostate-specific antigen (PSA) measurement and digital rectal examination (DRE). PSA is a glycoprotein produced by prostate epithelial cells; elevated PSA is not specific to cancer because it can rise with benign prostatic hyperplasia (BPH), prostatitis, urinary retention, and recent instrumentation. Therefore, PSA must be interpreted using age-specific reference ranges, PSA kinetics, and risk calculators.

When screening or clinical concern persists, diagnostic confirmation typically involves prostate biopsy. Contemporary practice often uses multiparametric magnetic resonance imaging (mpMRI) to improve targeting of suspicious lesions and reduce unnecessary biopsies. mpMRI evaluates lesion morphology, diffusion, and contrast enhancement; findings are commonly reported using PIRADS (Prostate Imaging Reporting and Data System). Lesions with higher PIRADS scores generally correlate with higher likelihood of clinically significant cancer. Biopsy strategies can include targeted cores directed by MRI plus systematic sampling.

Histopathology defines the definitive diagnosis. The Gleason grading system, updated in modern formulations, categorizes tumor architecture patterns and produces a Grade Group (1–5). Grade Group reflects biological aggressiveness and influences management decisions. Tumor staging assesses local extension and metastatic spread using imaging modalities such as CT and bone scan in appropriate risk contexts, with more sensitive approaches (including PSMA PET/CT) increasingly used for detection of metastatic disease.

Management depends on risk category and life expectancy. For low-risk disease (typically limited volume, lower Grade Group), active surveillance is frequently recommended. Active surveillance involves structured PSA monitoring, repeat DRE, periodic mpMRI, and repeat biopsy in selected intervals to detect upgrading. The goal is to avoid treatment-related harms while maintaining the ability to intervene curatively upon progression.

Intermediate-risk and high-risk cancers may require definitive therapy. Radiation therapy (external beam or brachytherapy) is a major curative option, often combined with androgen deprivation therapy (ADT) for higher-risk disease. Surgical approaches include radical prostatectomy with pelvic lymph node assessment, with potential advantages in pathological staging and the ability to quantify margins and nodal status.

Advanced or metastatic disease is managed systemically. ADT reduces androgen signaling, often with agents such as LHRH agonists/antagonists and androgen receptor pathway inhibitors (e.g., abiraterone, enzalutamide, apalutamide, darolutamide). Chemotherapy with docetaxel is used in selected metastatic castration-sensitive settings. In castration-resistant disease, sequential therapies, including additional androgen pathway inhibitors, chemotherapy, radiopharmaceuticals (when indicated), and targeted approaches based on molecular profiling, guide treatment selection.

Supportive care is integral. ADT and cancer therapies can cause hot flashes, sexual dysfunction, fatigue, anemia, metabolic changes, bone loss, and cardiovascular risk alterations. Clinicians use lifestyle counseling, bone health measures (e.g., calcium/vitamin D and consideration of bone-protective agents), cardiovascular risk management, and rehabilitation strategies. Monitoring involves serial PSA and imaging when indicated, while tracking treatment toxicities with validated symptom and function assessments.

Genomic and biomarker profiling is emerging to refine prognosis and guide therapy. Tumors with actionable alterations may qualify for targeted treatments, and immunotherapy considerations depend on specific molecular contexts. In practice, shared decision-making is essential: the patient’s values regarding longevity, quality of life, and tolerance for surveillance versus treatment must be integrated with clinical risk.

In summary, prostate cancer care is a continuum from screening and diagnosis to risk-adapted treatment. Accurate interpretation of PSA, strategic use of mpMRI and targeted biopsy, reliable Gleason/Grade Group assessment, and modern imaging for staging enable clinicians to distinguish indolent from clinically significant disease. Active surveillance can preserve quality of life for low-risk patients, while radiation, surgery, and systemic therapies address progressively higher-risk phenotypes. Source: BigTimeToronto (creator of the provided post)